Skip to main content

Emerging applications of aptamers for anticoagulation and hemostasis.

Publication ,  Journal Article
Chabata, CV; Frederiksen, JW; Sullenger, BA; Gunaratne, R
Published in: Curr Opin Hematol
September 2018

PURPOSE OF REVIEW: Since the selection of the first thrombin-binding aptamer in 1992, the use of nucleic acid aptamers to target specific coagulation factors has emerged as a valuable approach for generating novel anticoagulant and procoagulant therapeutics. Herein, we highlight the most recent discoveries involving application of aptamers for those purposes. RECENT FINDINGS: Learning from the successes and pitfalls of the FIXa-targeting aptamer pegnivacogin in preclinical and clinical studies, the latest efforts to develop antidote-controllable anticoagulation strategies for cardiopulmonary bypass that avoid unfractionated heparin involve potentiation of the exosite-binding factor X (FX)a aptamer 11F7t by combination with either a small molecule FXa catalytic site inhibitor or a thrombin aptamer. Recent work has also focused on identifying aptamer inhibitors of contact pathway factors such as FXIa and kallikrein, which may prove to be well tolerated and effective antithrombotic agents in certain clinical settings. Finally, new approaches to develop procoagulant aptamers to control bleeding associated with hemophilia and other coagulopathies involve targeting activated protein C and tissue plasminogen activator. SUMMARY: Overall, these recent findings exemplify the versatility of aptamers to modulate a variety of procoagulant and anticoagulant factors, along with their capacity to be used complementarily with other aptamers or drugs for wide-ranging applications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Hematol

DOI

EISSN

1531-7048

Publication Date

September 2018

Volume

25

Issue

5

Start / End Page

382 / 388

Location

United States

Related Subject Headings

  • Kallikreins
  • Immunology
  • Humans
  • Hemostasis
  • Hemophilia A
  • Factor Xa Inhibitors
  • Factor IXa
  • Catalytic Domain
  • Cardiopulmonary Bypass
  • Aptamers, Nucleotide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chabata, C. V., Frederiksen, J. W., Sullenger, B. A., & Gunaratne, R. (2018). Emerging applications of aptamers for anticoagulation and hemostasis. Curr Opin Hematol, 25(5), 382–388. https://doi.org/10.1097/MOH.0000000000000452
Chabata, Charlene V., James W. Frederiksen, Bruce A. Sullenger, and Ruwan Gunaratne. “Emerging applications of aptamers for anticoagulation and hemostasis.Curr Opin Hematol 25, no. 5 (September 2018): 382–88. https://doi.org/10.1097/MOH.0000000000000452.
Chabata CV, Frederiksen JW, Sullenger BA, Gunaratne R. Emerging applications of aptamers for anticoagulation and hemostasis. Curr Opin Hematol. 2018 Sep;25(5):382–8.
Chabata, Charlene V., et al. “Emerging applications of aptamers for anticoagulation and hemostasis.Curr Opin Hematol, vol. 25, no. 5, Sept. 2018, pp. 382–88. Pubmed, doi:10.1097/MOH.0000000000000452.
Chabata CV, Frederiksen JW, Sullenger BA, Gunaratne R. Emerging applications of aptamers for anticoagulation and hemostasis. Curr Opin Hematol. 2018 Sep;25(5):382–388.

Published In

Curr Opin Hematol

DOI

EISSN

1531-7048

Publication Date

September 2018

Volume

25

Issue

5

Start / End Page

382 / 388

Location

United States

Related Subject Headings

  • Kallikreins
  • Immunology
  • Humans
  • Hemostasis
  • Hemophilia A
  • Factor Xa Inhibitors
  • Factor IXa
  • Catalytic Domain
  • Cardiopulmonary Bypass
  • Aptamers, Nucleotide